By Cara Salvatore (January 24, 2022, 10:03 PM EST) — A former DEA official testified Monday in a Washington state opioid trial that at least one of the “Big Three” drug distributors raised pharmacy controlled-substance order caps for unjustifiable reasons, and more than one didn’t “seem to understand” their obligations to report suspicious orders.
Ruth Carter, an expert formerly with the Drug Enforcement Administration, returned to the stand Monday after a two-week break in a Seattle bench trial, running since November, in which Washington’s attorney general seeks to hold distributors AmerisourceBergen, Cardinal Health and McKesson accountable for allegedly helping to fuel an opioid addiction crisis in the state.
On redirect Monday,…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
- Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
- Create custom alerts for specific article and case topics and so much more!
TRY LAW360 FREE FOR SEVEN DAYS